Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
Jazz Pharmaceuticals (Nasdaq: JAZZ) has scheduled its 2025 first quarter financial results announcement for Tuesday, May 6, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss the results and provide business updates.
The global biopharma company, headquartered in Dublin, focuses on developing life-changing medicines for serious diseases, with a portfolio including therapies for sleep disorders, epilepsy, and cancer treatments. Participants are advised to register 15 minutes before the scheduled webcast, which can be accessed through the Investors section of Jazz Pharmaceuticals' website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 6 maggio 2025, dopo la chiusura del mercato statunitense. L'azienda terrà una webcast audio in diretta alle 16:30 ET / 21:30 IST per discutere i risultati e fornire aggiornamenti aziendali.
La società biofarmaceutica globale, con sede a Dublino, si concentra sullo sviluppo di farmaci innovativi per malattie gravi, con un portafoglio che include terapie per disturbi del sonno, epilessia e trattamenti oncologici. Si consiglia ai partecipanti di registrarsi 15 minuti prima della webcast, accessibile nella sezione Investitori del sito web di Jazz Pharmaceuticals.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 6 de mayo de 2025, después del cierre del mercado estadounidense. La compañía realizará una transmisión de audio en vivo a las 4:30 p.m. ET / 9:30 p.m. IST para discutir los resultados y ofrecer actualizaciones comerciales.
La empresa biofarmacéutica global, con sede en Dublín, se enfoca en desarrollar medicamentos que cambian la vida para enfermedades graves, con un portafolio que incluye terapias para trastornos del sueño, epilepsia y tratamientos contra el cáncer. Se recomienda a los participantes registrarse 15 minutos antes de la transmisión, que estará disponible en la sección de Inversores del sitio web de Jazz Pharmaceuticals.
Jazz Pharmaceuticals (나스닥: JAZZ)는 2025년 1분기 재무 실적 발표를 2025년 5월 6일 화요일 미 증시 마감 후에 예정했습니다. 회사는 오후 4시 30분 ET / 오후 9시 30분 IST에 실적을 논의하고 사업 업데이트를 제공하는 라이브 오디오 웹캐스트를 진행할 예정입니다.
더블린에 본사를 둔 글로벌 바이오제약 회사인 Jazz Pharmaceuticals는 심각한 질병을 위한 혁신적인 의약품 개발에 주력하고 있으며, 수면 장애, 간질, 암 치료제를 포함한 포트폴리오를 보유하고 있습니다. 참가자는 웹캐스트 시작 15분 전에 등록할 것을 권장하며, 등록은 Jazz Pharmaceuticals 웹사이트의 투자자 섹션에서 가능합니다.
Jazz Pharmaceuticals (Nasdaq : JAZZ) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 6 mai 2025, après la clôture du marché américain. La société organisera une diffusion audio en direct à 16h30 ET / 21h30 IST pour discuter des résultats et fournir des mises à jour commerciales.
Cette entreprise biopharmaceutique mondiale, dont le siège est à Dublin, se concentre sur le développement de médicaments innovants pour des maladies graves, avec un portefeuille comprenant des thérapies pour les troubles du sommeil, l'épilepsie et les traitements contre le cancer. Il est conseillé aux participants de s'inscrire 15 minutes avant la diffusion, accessible via la section Investisseurs du site web de Jazz Pharmaceuticals.
Jazz Pharmaceuticals (Nasdaq: JAZZ) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 6. Mai 2025, nach Börsenschluss in den USA geplant. Das Unternehmen wird um 16:30 Uhr ET / 21:30 Uhr IST eine Live-Audio-Webcast veranstalten, um die Ergebnisse zu besprechen und geschäftliche Updates zu geben.
Das global tätige Biopharma-Unternehmen mit Hauptsitz in Dublin konzentriert sich auf die Entwicklung lebensverändernder Medikamente für schwere Krankheiten und verfügt über ein Portfolio, das Therapien für Schlafstörungen, Epilepsie und Krebsbehandlungen umfasst. Teilnehmer werden gebeten, sich 15 Minuten vor Beginn des Webcasts anzumelden, der über den Investor-Bereich der Website von Jazz Pharmaceuticals zugänglich ist.
- None.
- None.
Audio webcast/conference call:
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 5080203
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Jeff Macdonald
Exec Dir, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-6-2025-302434748.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) release Q1 2025 earnings?
How can investors access JAZZ's Q1 2025 earnings call?
What are the main therapeutic areas for Jazz Pharmaceuticals (JAZZ)?
Where is Jazz Pharmaceuticals (JAZZ) headquartered?
